Imunon Is Maintained at Buy by EF Hutton
Imunon Analyst Ratings
Imunon Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Imunon, Maintains $14 Price Target
Imunon Analyst Ratings
HC Wainwright & Co. : Maintaining the Imunon (IMNN.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $13.00 to $12.00.
Imunon Analyst Ratings
HC Wainwright & Co. Maintains Buy on Imunon, Lowers Price Target to $12
Imunon's Promising Clinical Trials and Strategic Advances Merit a Buy Rating
Imunon Analyst Ratings
HC Wainwright & Co. Maintains Buy on Imunon, Raises Price Target to $13
Analysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Legend Biotech (LEGN) and Imunon (IMNN)
Imunon Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Imunon (IMNN) and CalciMedica (CALC)
Positive Interim OVATION 2 Data Bolsters Confidence in Imunon Stock: An Analysis of Emily Bodnar's Buy Rating
Analysts Have Conflicting Sentiments on These Healthcare Companies: Imunon (IMNN) and Laboratory (LH)
HC Wainwright & Co. Reiterates Buy on Imunon, Maintains $12 Price Target
Imunon Analyst Ratings
Imunon Analyst Ratings
H.C. Wainwright Reaffirms Their Buy Rating on Imunon (IMNN)
No Data
No Data